Moshe Talpaz Selected Research

Fatigue

1/2020	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
1/2017	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
8/2014	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
4/2013	Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
3/2011	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
6/2003	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Moshe Talpaz Research Topics

Disease

93	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 01/2000
43	Philadelphia Chromosome 12/2019 - 02/2002
40	Neoplasms (Cancer) 04/2021 - 05/2003
35	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 03/2003
22	Leukemia 12/2021 - 03/2003
13	Thrombocytopenia (Thrombopenia) 01/2022 - 09/2002
10	Splenomegaly 01/2021 - 10/2004
10	Anemia 01/2020 - 04/2002
10	Disease Progression 12/2019 - 03/2002
9	Multiple Myeloma 12/2019 - 03/2003
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 06/2003
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018 - 06/2004
7	Blast Crisis (Blast Phase) 02/2011 - 05/2002
6	Fatigue 01/2020 - 06/2003
5	Neutropenia 01/2016 - 06/2003
4	Melanoma (Melanoma, Malignant) 02/2021 - 04/2007
4	Fibrosis (Cirrhosis) 01/2021 - 07/2004
4	Pancreatitis 12/2019 - 11/2012
3	Nausea 01/2020 - 12/2003
3	Diarrhea 01/2017 - 12/2003
3	Genetic Translocation (Chromosomal Translocation) 01/2017 - 04/2015
3	Exanthema (Rash) 01/2016 - 08/2014
3	Polycythemia Vera 08/2015 - 06/2003
3	Hematologic Neoplasms (Hematological Malignancy) 06/2013 - 02/2003
3	Chromosome Aberrations (Chromosome Abnormalities) 12/2010 - 05/2002
3	Residual Neoplasm 10/2007 - 01/2003
2	Carcinoma (Carcinomatosis) 04/2021 - 01/2019
2	Wernicke Encephalopathy (Wernicke's Encephalopathy) 01/2021 - 07/2017
2	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 02/2013
2	Inflammation (Inflammations) 01/2020 - 08/2003
2	Cytopenia 12/2019 - 05/2002
2	Leukocytosis (Pleocytosis) 08/2015 - 12/2003
2	Essential Thrombocythemia 03/2011 - 06/2005
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2003 - 06/2003
2	Edema (Dropsy) 12/2003 - 08/2002
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2003 - 08/2002
1	Hemorrhage 01/2022

Drug/Important Bio-Agent (IBA)

70	Imatinib Mesylate (Gleevec)FDA Link 10/2017 - 01/2000
22	ruxolitinibIBA 01/2022 - 03/2012
21	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2003
17	Phosphotransferases (Kinase)IBA 12/2019 - 01/2003
15	Proteins (Proteins, Gene)FDA Link 02/2021 - 03/2002
15	Interferon-alpha (Interferon Alfa)IBA 04/2015 - 01/2000
9	fedratinibIBA 01/2022 - 03/2011
9	bcr-abl Fusion ProteinsIBA 11/2013 - 01/2000
8	Janus Kinase InhibitorsIBA 01/2022 - 04/2013
7	InterferonsIBA 12/2021 - 06/2003
7	ponatinibIBA 11/2021 - 11/2012
7	CytokinesIBA 01/2021 - 07/2003
7	Dasatinib (BMS 354825)FDA Link 01/2018 - 10/2005
7	Pharmaceutical PreparationsIBA 06/2015 - 05/2002
6	Deubiquitinating EnzymesIBA 02/2021 - 11/2010
5	Janus Kinase 2IBA 05/2021 - 12/2013
5	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 12/2010
5	Transcription Factors (Transcription Factor)IBA 02/2021 - 08/2003
5	Biological ProductsIBA 01/2021 - 12/2003
5	Janus Kinase 1IBA 01/2018 - 10/2013
5	degrasynIBA 06/2015 - 04/2007
5	Cytarabine (Cytosar-U)FDA LinkGeneric 09/2005 - 05/2002
4	Janus KinasesIBA 01/2022 - 03/2012
4	NF-kappa B (NF-kB)IBA 01/2021 - 08/2003
4	Lipase (Acid Lipase)FDA Link 12/2019 - 11/2012
3	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2022 - 01/2018
3	RNA (Ribonucleic Acid)IBA 04/2021 - 11/2011
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2021 - 07/2014
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 11/2013
3	Erythropoietin FDA Link 10/2013 - 04/2002
3	Reticulin (Reticular Fiber)IBA 08/2005 - 07/2004
3	Hemoglobins (Hemoglobin)IBA 05/2005 - 04/2002
2	LigandsIBA 10/2019 - 12/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2019 - 08/2003
2	glasdegibIBA 06/2019 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 02/2002
2	INCB039110IBA 01/2018 - 01/2017
2	nilotinib FDA Link 01/2018 - 01/2007
2	Proteasome InhibitorsIBA 01/2016 - 08/2014
2	marizomibIBA 01/2016 - 08/2014
2	Bortezomib (Velcade)FDA Link 08/2014 - 10/2009
2	UbiquitinIBA 12/2011 - 08/2011
2	Biomarkers (Surrogate Marker)IBA 11/2011 - 02/2008
2	Tyrosine (L-Tyrosine)FDA Link 04/2008 - 10/2005
2	Protein Isoforms (Isoforms)IBA 12/2006 - 01/2004
2	TransferasesIBA 01/2006 - 03/2003
2	Decitabine FDA Link 06/2005 - 08/2003
2	tipifarnib (R115777)IBA 12/2003 - 03/2003
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2003 - 02/2002
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2003 - 07/2003
2	HomoharringtonineIBA 09/2003 - 04/2002
1	Interleukin-1 Receptor-Associated KinasesIBA 01/2022
1	AntigensIBA 12/2021
1	EnzymesIBA 02/2021
1	Ubiquitin-Specific ProteasesIBA 02/2021

Therapy/Procedure

83	Therapeutics 01/2022 - 04/2002
4	Drug Tapering 01/2018 - 06/2003
3	Stem Cell Transplantation 07/2003 - 09/2002
2	Cell Transplantation 12/2021 - 12/2020
2	Precision Medicine 09/2015 - 03/2008
2	Drug Therapy (Chemotherapy) 12/2006 - 03/2005
2	Aftercare (After-Treatment) 02/2003 - 08/2002
1	Homologous Transplantation 12/2021